Clinical researchers at the Institute of Ophthalmology, University College London, UK, and Moorfields Eye Hospital NHS Foundation Trust, London, have presented a novel deep learning… Read More »Clinical study of >3,500 IRD patients reports novel genotype-phenotype associations using optical coherence tomography (OCT) imaging.
Beacon Therapeutics Holdings Limited, based in London, UK and Cambridge, Massachusetts, have announced the completion of enrolment in its registrational Phase 2/3 VISTA trial evaluating… Read More »Beacon Therapeutics announce the completion of enrolment for the Phase 2/3 trial for “laru-zova”, for the treatment of XLRP.
Dear EURETINA Members, A very warm welcome to the July 21st, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »July 21st, 2025 “EURETINA-Brief”© Issue No. 321
Researchers at the Department of Ophthalmology and Visual Sciences, University of British Columbia, Canada, have reported the first example of a beta-tubulin 4B gene variant… Read More »First report of a beta-tubulin 4B gene variant (TUBB4B) with RP, late-onset and progressive sensorineural hearing loss.
Researchers in Canada, have reported the first quantitative choroidal assessment in a cohort of patients with genetically characterized retinitis pigmentosa (RP). The results of the… Read More »First quantitative choroidal assessment may be valuable for using other standard metrics for retinal clinical trial evaluations.
Atsena Therapeutics, based in Durham, North Carolina, has announced that the U.S. Food and Drug Administration (FDA) has agreed to the expansion of the company’s… Read More »Astena Therapeutics has announced an expansion of a Phase 1 / 2 study into a continuous Phase 1 / 2 / 3 trial, agreed by U.S. Food and Drug Administration (FDA).
Dear EURETINA Members, A very warm welcome to the July 7th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »July 7th, 2025 “EURETINA-Brief”© Issue No. 320
Researchers based in the Institute of Ophthalmology, University College London, and Moorfields Eye Hospital, London, UK have presented a deep learning model – “Eye2gene” –… Read More »Eye2Gene performance of genetic diagnosis showed better results from any single human ophthalmic expert.
Economic estimates have indicated that 2.25 billion coffees are consumed every day – this is a significant number. Researchers at the Department of Ophthalmology, Hubei… Read More »Anyone for a coffee – instant coffee may increase the risk of AMD, and reducing instant coffee intake can prevent dry AMD.
Clinical trial research on the treatment of sub-cutaneous (subQ) migaldendranib (MGB), sponsored by Ashvattha Therapeutics, has announced interim results from an ongoing Phase II study… Read More »Potential paradigm shift of anti-VEGF treatment with sub-cutaneous injections at home, following Phase II summary results.
